# Biotech Buzz: Market Flops and Oil Jitters!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-03-27T14:01:43.381Z
Source: https://newsyai.com/edition/25af1502-2e93-4563-a72b-425a4dbf4347
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

# Biotech Bullshit Sequel: Futures Fizzle, Oil Jiggles on Iran Jizz-Jab!

**Premarket prick-tease**—**Dow futures -0.4% ~46,000**[[1]](https://www.cnn.com/markets/premarkets)[[2]](https://www.benzinga.com/premarket), **S&P -0.2% ~6,600**[[1]](https://www.cnn.com/markets/premarkets), **Nasdaq -0.15% ~24,300**[[2]](https://www.benzinga.com/premarket) as WTI crude **dongs at ~$96** amid Trump-Iran truce teases and supply spook revival—energy erections twitch, biotechs blast cumshots again.[[1]](https://oilprice.com/) [[2]](https://www.cnbc.com/quotes/@CL.1) ARTL ass-rocket, ONCO orgasm, SLND slapdown—bulls balls-deep, bears bitch bankruptcy. First-principles prick-poke incoming.[[3]](https://stockanalysis.com/markets/premarket/gainers)

---

## 1) Artelo Biosciences (ARTL): “GLP-1 Glaucoma Glory Hole” vs “Reverse-Split Rug-Pull”

**Why it’s loud**  
**ARTL** detonating **+149% pre to ~$8** biotech boner supreme—third-party funded glaucoma study on ART27.13 companion to GLP-1s, eye-candy expansion into $16B market.[[3]](https://stockanalysis.com/markets/premarket/gainers/) [[4]](https://finance.yahoo.com/quote/ARTL/)

**Bull case (endocannabinoid eye-fuck euphoria)**  
ART27.13 peripheral CB1 blocker squirts IOP drop potential sans side effects, fully funded Vanderbilt collab = no cash burn, cancer pipeline bonus for multi-bagger moon to $20+.[[5]](https://ir.artelobio.com/news-events/press-releases)

**Bear case (serial splitter scam-shit)**  
Fresh 3:1 reverse split reeks dilution desperation, microcap meme volatility vomit, history of hype-farts without FDA cum.[[6]](https://www.marketwatch.com/investing/stock/artl)

**My take, first principles (CB1 moat vs money pit)**  
Boil the biology: Selective peripheral modulation = real edge in glaucoma stack if data dongs, but funding facade hides burn—oil irrelevant flyer. **Scoop $7.50-7.80**, **$10/$12 calls** study spurt—**puts $6.50** split stink. Risk: Trial tease flop.[[4]](https://finance.yahoo.com/quote/ARTL)

---

## 2) Onconetix (ONCO): “Nasdaq Lifeline Load-Up” vs “Merger Dump Dilution”

**Why it’s loud**  
**ONCO** surging **+82% pre to ~$5.80** oncology overachiever—Nasdaq panel grants compliance extension, $12.9M Series D/warrants financing juices runway despite Ocuvex merger nix.[[7]](https://www.benzinga.com/premarket/) [[8]](https://ir.onconetix.com/news-releases)

**Bull case (prostate punch revival)**  
Favorable hearing = listing lifeline, cash infusion funds men's health pivot (Realbotix sexbot tie-in?), oncology pipeline prick for $10+ squeeze.[[9]](https://www.stocktitan.net/news/ONCO/)

**Bear case (offering overdose obituary)**  
Merger termination = red flag flop, private placement dilution dick-slap incoming, penny pump prone to rug.[[10]](https://finance.yahoo.com/quote/ONCO/)

**My take, first principles (financing fix vs fuckery)**  
Core the cash: Extension buys trial time, but warrants = shareholder shaft if exercised. Biotech bingo. **Buy $5.20-5.50**, **$7/$9 calls** lifeline lift—**puts $4.50** dump dive. Risk: More offerings.[[3]](https://stockanalysis.com/markets/premarket/gainers)

---

## 3) Southland Holdings (SLND): “$118M Project Prick” vs “$89M Lawsuit Limp”

**Why it’s loud**  
**SLND** cratering **-29% pre to ~$1.15** infra implosion—$118M data center/data projects NTP glow, but annual report coughs $89M legal liability bomb on convention fiasco.[[11]](https://stockanalysis.com/markets/premarket/losers/) [[12]](https://ir.southlandholdings.com/press-releases)

**Bull case (backlog bonanza build)**  
$2B backlog bulge with infra spend orgasm, recent wins signal rebound to $5+ on execution erect.[[13]](https://www.stocktitan.net/sec-filings/SLND/10-k-southland-holdings-inc-files-annual-report-684a0ce146a5.html)

**Bear case (liability lawsuit laceration)**  
Revenue reversal + $89M hit guts profits, execution risks in recession = bankruptcy balls-off.[[14]](https://www.benzinga.com/markets/equities/26/03/51474269/why-southland-holdings-slnd-surged-53-after-hours)

**My take, first principles (backlog ballast vs liability leak)**  
Strip the structure: Fat backlog moats if lawsuits settle soft, but legal drag = margin murder. Oil indirect via infra. **Grab $1.10-1.20**, **$1.80/$2.20 calls** project pop—**puts $0.90** liability limp. Risk: More reversals.[[5]](https://stockanalysis.com/markets/premarket/losers)

---

## Tape-Side Tactics (biotech blast or infra bust?)

- **ARTL**: **$7.50-7.80** glaucoma glory; **$10C/$12C** spreads, **P$6.50** split shit. [[3]](https://stockanalysis.com/markets/premarket/gainers/)  
- **ONCO**: **$5.20-5.50** lifeline load; **$7C/$9C**, **P$4.50** dilution dump. [[7]](https://www.benzinga.com/premarket/)  
- **SLND**: **$1.10-1.20** backlog balls; **$1.80C/$2.20C**, **P$0.90** lawsuit lash. [[11]](https://stockanalysis.com/markets/premarket/losers/)  

Iran itch or itch-scratch? Biotech hump or dump. DYOR, balls to the wall.
